MDS is a bone marrow failure disorder
MDS is a blood cancer
Learn More >

Welcome to the MDS Patient Message Board Post New Thread

Welcome to the MDS Patient Message Board. We hope that you will find this to be a very valuable resource in your journey. We have recently revised the format of our forum to be much more user friendly and pleasing on the eyes. Let us know if you have any problems, or if you have additional suggestions on how we might further improve our site.

AML and remission

Home forums Patient Message Board AML and remission

This topic contains 1 reply, has 2 voices, and was last updated by  mdsfound 3 months ago.

Viewing 2 posts - 1 through 2 (of 2 total)
  • Author
    Posts
  • #46320

    Linda gottlieb
    Participant

    My husband is 71 yo and was initially do with MDS 3 yrs ago. After 1yr of wait and see his counts went to 9% blasts and he started Dracgen on 1week/3 week rotation. After 6 Td he went into remission for 1 1/2 yrs and now he has AML – blasts 20%. He is back on same tx with same cycle in the hopes of going into remission again. Has anyone experienced remission from AML? How many Rounds before results were seen.? Effects from Chemo are worse this time around as he is having difficulty with breathing. And walking and severe fatigue. He is not candidate for stem cell or steroids due to heart, diabetis, and severe scoliosis. Two weeks post chemo..wbc 1.7, hemoglobin 10.1 platelets 1200. Drs. Not forthcoming on prognosis, just say wait and see. Can use support ,ideas, and experiences.

    #46341

    mdsfound
    Moderator

    Dear Linda, Thank you for sharing information regarding your husband’s health. Huge breakthroughs have been made in recent years in regard to understanding the genomic landscape for AML and how to best manage this rare cancer. Syros has promising clinical data from their ongoing Phase 2 Trial of SY-1425 in Genomically Defined AML and MDS Patients…Tolero Pharmaceuticals also has an ongoing Phase 2 Zella 201 Study… Daiichi Sankyo has a new drug application for FLT3 Inhibitor Quizartinib for Treatment of Patients with Relapsed/Refractory FLT3-ITD AML… and Agios has the Ivosidenib Phase 1 Dose-Escalation and Expansion Trial in IDH1 Mutant Positive Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Ineligible for Standard Treatment and Myelodysplastic Syndrome (MDS)…just to name a few.

Viewing 2 posts - 1 through 2 (of 2 total)

Register for an account, or login to post to our message boards. Click here.

You must be logged in to reply to this topic.


Login

Login

Search Forums

Review answers to commonly asked questions or get answers to your questions from an MDS expert